Article | February 13, 2020

Gaining Approval For Manufacturing IT Investments

By Christian Woelbeling, Thomas Zimmer, and Christoph Herwig

Gaining Approval for Manufacturing IT Investments

It’s no question that in the digital age, pharma and biotech production must be supported by manufacturing execution systems (MES). These systems digitize end-to-end pharma manufacturing processes – from receiving goods via warehousing through to production and packaging. Using MES results in process improvements and significant efficiency savings.

Pharma manufacturing without MES is a risky strategy
If you are still documenting your pharma production processes on paper, there is a constant potential threat of human errors, data integrity violations and warning letters. An incident can put your entire production on hold. So if you think the implementation of MES just costs money and lacks ROI, think twice.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

Werum IT Solutions America, Inc.